Philip Kaye

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association

Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis